News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
227,514 Results
Type
Article (5058)
Company Profile (18)
Press Release (222438)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82217)
Career Advice (461)
Deals (15047)
Drug Delivery (8)
Drug Development (19068)
Employer Resources (30)
FDA (3677)
Job Trends (3901)
News (120128)
Policy (7507)
Tag
Academia (293)
Accelerated approval (2)
Adcomms (3)
Allergies (10)
Alliances (14806)
ALS (26)
Alzheimer's disease (264)
Antibody-drug conjugate (ADC) (13)
Approvals (3705)
Artificial intelligence (55)
Autoimmune disease (7)
Automation (4)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (18)
Biotechnology (21)
Bladder cancer (16)
Brain cancer (7)
Breast cancer (57)
Cancer (572)
Cardiovascular disease (31)
Career advice (393)
Career pathing (3)
CAR-T (44)
CDC (2)
Cell therapy (123)
Cervical cancer (2)
Clinical research (16218)
Collaboration (226)
Compensation (237)
Complete response letters (3)
COVID-19 (302)
CRISPR (13)
C-suite (159)
Cystic fibrosis (19)
Data (715)
Denatured (1)
Depression (12)
Diabetes (53)
Diagnostics (2057)
Digital health (4)
Diversity, equity & inclusion (13)
Drug discovery (19)
Drug pricing (9)
Drug shortages (2)
Duchenne muscular dystrophy (22)
Earnings (41482)
Editorial (3)
Employer branding (6)
Employer resources (32)
Events (38210)
Executive appointments (374)
FDA (4095)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (237)
Gene editing (21)
Generative AI (2)
Gene therapy (68)
GLP-1 (123)
Government (416)
Guidances (111)
Healthcare (5043)
HIV (9)
Huntington's disease (3)
IgA nephropathy (7)
Immunology and inflammation (21)
Indications (10)
Infectious disease (318)
Inflammatory bowel disease (28)
Inflation Reduction Act (3)
Influenza (3)
Intellectual property (19)
Interviews (53)
IPO (7864)
IRA (3)
Job creations (1121)
Job search strategy (360)
Kidney cancer (9)
Labor market (5)
Layoffs (100)
Leadership (5)
Legal (2336)
Liver cancer (19)
Longevity (2)
Lung cancer (65)
Lymphoma (38)
Machine learning (1)
Management (10)
Manufacturing (76)
MASH (34)
Medical device (3879)
Medtech (3880)
Mergers & acquisitions (7478)
Metabolic disorders (152)
Multiple sclerosis (10)
NASH (6)
Neurodegenerative disease (19)
Neuropsychiatric disorders (1)
Neuroscience (400)
NextGen: Class of 2025 (1674)
Non-profit (730)
Now hiring (3)
Obesity (65)
Opinion (30)
Ovarian cancer (19)
Pain (19)
Pancreatic cancer (20)
Parkinson's disease (36)
Partnered (4)
Patents (31)
Patient recruitment (46)
Peanut (5)
People (24794)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (4846)
Phase II (7049)
Phase III (5605)
Pipeline (811)
Policy (12)
Postmarket research (625)
Preclinical (1898)
Press Release (66)
Prostate cancer (41)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (98)
Real estate (1876)
Recruiting (8)
Regulatory (5215)
Reports (17)
Research institute (302)
Resumes & cover letters (68)
Rett syndrome (8)
Schizophrenia (27)
Series A (39)
Series B (31)
Sickle cell disease (8)
Special edition (1)
Spinal muscular atrophy (29)
Sponsored (4)
Startups (1014)
Stomach cancer (1)
Supply chain (12)
Tariffs (5)
The Weekly (1)
Vaccines (49)
Venture capital (3)
Weight loss (24)
Women's health (2)
Date
Today (53)
Last 7 days (165)
Last 30 days (499)
Last 365 days (9354)
2025 (5309)
2024 (11027)
2023 (13193)
2022 (18658)
2021 (19679)
2020 (18239)
2019 (13205)
2018 (10205)
2017 (10004)
2016 (9157)
2015 (12118)
2014 (9588)
2013 (7707)
2012 (8330)
2011 (8796)
2010 (8634)
Location
Africa (185)
Alabama (15)
Alaska (2)
Arizona (63)
Arkansas (1)
Asia (11558)
Australia (1635)
California (2447)
Canada (862)
China (94)
Colorado (103)
Connecticut (108)
Delaware (44)
Europe (24840)
Florida (377)
Georgia (43)
Idaho (24)
Illinois (126)
India (7)
Indiana (76)
Iowa (7)
Japan (107)
Kansas (26)
Kentucky (13)
Louisiana (6)
Maine (43)
Maryland (268)
Massachusetts (1982)
Michigan (90)
Minnesota (159)
Mississippi (1)
Missouri (26)
Montana (16)
Nebraska (12)
Nevada (31)
New Hampshire (16)
New Jersey (731)
New Mexico (5)
New York (581)
North Carolina (375)
North Dakota (4)
Northern California (1192)
Ohio (77)
Oklahoma (5)
Oregon (4)
Pennsylvania (427)
Puerto Rico (1)
Rhode Island (15)
South America (276)
South Carolina (10)
Southern California (881)
Tennessee (49)
Texas (306)
United States (8807)
Utah (71)
Virginia (64)
Washington D.C. (15)
Washington State (212)
West Virginia (2)
Wisconsin (29)
227,514 Results for "cytrx corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
CytRx Corporation Relaunches as LadRx Corporation
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.
September 23, 2022
·
4 min read
Business
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board”).
August 9, 2022
·
4 min read
Deals
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).
May 17, 2022
·
4 min read
Biotech Beach
CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates
CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced that the Company is absorbing its wholly-owned subsidiary Centurion BioPharma Corporation.
March 9, 2022
·
4 min read
Policy
European Patent Office Awards CytRx Key Patent
CytRx Corporation, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced it has been awarded a key patent by the European Patent Office, and that the period for parties to oppose the patent has lapsed without opposition.
September 7, 2022
·
3 min read
Venture capitalists
The Top 5 Most Active Corporate VCs in Pharma
BioSpace
examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made headlines last year with its $16.5 billion Catalent buy, topped the list.
May 21, 2025
·
5 min read
·
Annalee Armstrong
Press Releases
Orion Corporation’s financial reporting and Annual General Meeting in 2026
July 18, 2025
·
1 min read
Biotech Beach
CytRx Partners with Oncology Development Expert to Advance LADR Platform
CytRx Corporation announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.
April 20, 2022
·
4 min read
Business
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022.
January 3, 2022
·
4 min read
Biotech Beach
CytRx Highlights Orphazyme’s Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
CytRx Corporation today highlighted Orphazyme A/S for the treatment of Niemann-Pick disease type C (“NPC”). CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.
February 14, 2022
·
2 min read
1 of 22,752
Next
